The crystal structure of the neutral, distorted square planar copper(II) complex, viz. cis-[dichloro (N'-(2-benzyloxybenzylidene) pyridine-2-carboxamidrazone) copper(II)] (1) is reported which is the first well-characterized copper(II) complex of the series (space group C2/c, a = 18.414(5) Angstrom; b = 8.6510(10) Angstrom; c = 27.091(4) Angstrom; alpha = 90 degrees; beta = 109.800(17)degrees; gamma = 90 degrees; R-1 = 0.0331 wR(2) = 0.0852). The distortion from square planar geometry is thought to arise from the non-equivalent ligand donor set. The Cu-Cl bonds are equivalent with one of the Cl atoms making intermolecular contact at 2.6070 Angstrom with adjacent copper rendering a pseudo-square pyramidal geometry around copper. The complex is further characterized by UV/VIS spectroscopy, electrochemistry and magnetic susceptibility measurements. The in vitro antitumor activity of this complex and the parent ligand is determined against the human breast cancer cell-line MCF-7 which revealed that copper complexation renders a highly antiproliferative compound with IC50 value of 3 muM.
- copper complex
- antitumor activity
- breast cancer
Gokhale, N., Padhye, S., Rathbone, D., Billington, D., Lowe, P., Schwalbe, C., & Newton, C. (2001). The crystal structure of first copper(II) complex of a pyridine-2-carboxamidrazone - a potential antitumor agent. Inorganic Chemistry Communications , 4(1), 26-29. https://doi.org/10.1016/S1387-7003(00)00185-4